Alphatec Holdings is a medical technology company focused on the design, development, and advancement of technology for the surgical treatment of spine disorders. The company develops approach-specific procedural platforms, including Prone TransPsoas (PTP), Lateral TransPsoas (LTP), and Midline ALIF, which integrate proprietary SafeOp intra-operative nerve monitoring technology. Its portfolio includes IdentiTi porous titanium implants, InVictus Direct Vertebral Rotation instrumentation for deformity correction, and biologics. Alphatec also operates the EOS Imaging platform, which provides full-body, calibrated 3D imaging, and the EOS Insight software platform for automated alignment calculation and surgical planning. The company serves spine surgeons, hospitals, and healthcare systems primarily in the United States, with emerging international operations in Australia, New Zealand, and Japan. It markets its products through a network of independent sales agents and direct sales representatives. Alphatec acquired EOS Imaging and SafeOp to integrate advanced imaging and intra-operative data into its surgical solutions.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage atecspine.com
Sector Healthcare IR page investors.alphatecspine.com/overview/default.aspx
Tags
spine surgery, orthopedic implants, surgical robotics, medical imaging, nerve monitoring, titanium implants, deformity correction, biologics, surgical planning software, 3d imaging, InformatiX, ATEC Organic Innovation Machine, IdentiTi, SafeOp, Prone TransPsoas, PTP, EOS Imaging, Lateral TransPsoas, LTP, Midline ALIF, EOS Insight, InVictus Direct Vertebral Rotation, ATEC Experience, EOS Edge
Press page —

Metrics

Valuation  
Market cap $ 1.054B
Market cap (USD) $ 1.054B
P/E -12.13
PEG —
P/BV -457.84
P/S 1.26
P/OCF 17.18
P/FCF 343.75
Dividend yield —
Turnover / mcap —
Returns  
ROE -1,153.7%
ROI -24.8%
ROIC -10.7%
Profit margin -18.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 23
Quality score -23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Revenue 764.155M 611.562M 482.262M 350.867M 243.212M 144.861M 113.427M 91.694M 101.739M 120.248M 185.279M 206.98M 204.724M 196.278M 197.711M 171.61M 132.156M 101.313M — — 48.631M
Net profit -143.358M -162.123M -186.638M -152.149M -144.326M -78.994M -57.002M -28.975M -2.294M -29.925M -178.676M -12.882M -82.227M -15.459M -22.181M -14.355M -13.289M -29.288M — — -15.282M
Free cash flow 2.776M -127.874M -158.993M -124.596M -141.976M -69.543M -46.153M -32.122M -16.325M -18.856M -2.123M -31.571M -6.545M -4.053M 5.202M -28.861M -17.371M — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Share price 21.04 9.18 15.11 12.35 11.43 14.52 7.09 2.29 2.66 3.21 0.3 1.41 2.01 1.66 1.72 2.12 2.54 1.75 4.91 3 —
Price performance 12m 1.29 -0.39 0.22 0.08 -0.21 1.05 2.1 -0.14 -0.17 9.71 -0.79 -0.3 0.21 -0.03 -0.19 -0.17 0.46 -0.64 0.64 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 18.5M 14.8M 15.1M 16.2M 23.5M 41.9M 60.1M 72.6M 83M 97.3M
↳ YoY growth -51.7% -19.9% +1.8% +7.0% +45.7% +78.1% +43.4% +20.9% +14.3% +17.3%
↳ 5y CAGR -15.0% -18.4% -18.3% -16.8% -9.3% +17.7% +32.3% +36.9% +38.7% +32.8%
Borrowings, current (USD) 3.11M 3.31M 3.28M 489,000 4.2M 684,000 29.9M 3.62M 3.31M 129M
Borrowings, non-current (USD) 43.1M 37.8M 42.3M 53.4M 38M 326M 350M 511M 575M 501M
Lease liabilities (USD) — — — 2.24M 926,000 28.6M 31.4M 28.8M 33.8M 30.2M
Cash and deposits (USD) 19.6M 22.5M 29.1M 47.1M 108M 187M 84.7M 221M 139M 161M
Intangible assets (USD) 5.71M 5.25M 26.4M 25.6M 24.7M 85.3M 82.8M 102M 93.5M 93.5M
Right-of-use assets (USD) — — — 1.86M 1.18M 25.3M 28.4M 26.4M 34.7M 31.2M
Net debt (borrowings + leases - cash) (USD) — 18.6M 16.5M 9.06M -64.6M 169M 326M 323M 473M 500M
Cash flow detail
Operating cash flow (USD) -9.96M -8.73M -25.6M -33.1M -46.4M -73.4M -75.1M -78.5M -44.7M 45.2M
Purchases of property, plant and equipment (USD) -8.9M -7.6M -6.51M -13M -23.1M -68.5M -49.5M -80.5M -83.2M -42.5M
Purchases of intangible assets (USD) -250,000 — -400,000 — -755,000 — -8.83M -6.47M -9.91M -7.19M
Change in receivables (cash effect) (USD) 8M 4.15M -396,000 -1.3M -7.48M -10.1M -18.8M -12.8M -14.6M -21.9M
Change in inventories (cash effect) (USD) -5.74M 258,000 -6.02M -14.7M -18.2M -27.7M -20.7M -45.6M -54.7M -6.31M
Change in payables (cash effect) (USD) -4.87M -2.59M 16,000 6M 7.13M 757,000 9.8M 6.99M 9.67M -11.2M
Share buybacks (cash effect) (USD) — — — — — -25M — — — —
Interest paid (cash effect) (USD) -7.37M -4.7M -5.14M -5.97M -6.33M -5.03M -3.86M -17.3M -20.3M -23.8M
Income taxes paid (cash effect) (USD) -920,000 -107,000 -134,000 -161,000 -190,000 -223,000 -272,000 -333,000 -275,000 -389,000
Share-based compensation (USD) 1.63M 3.9M 5.3M 11M 17.7M 36.5M 40.6M 81.2M 73.3M 73.7M
Operating cash flow before change in receivables (USD) -18M -12.9M -25.2M -31.8M -38.9M -63.3M -56.3M -65.7M -30.1M 67.1M
Free cash flow (OCF - PPE - intangibles) (USD) -19.1M -16.3M -32.5M -46.2M -70.3M -142M -133M -165M -138M -4.41M
Income detail
Research and development expense (USD) 9.25M 4.92M 9.98M 13.8M 18.7M 32M 44M 70.1M 80.7M 76.3M
↳ 5y CAGR -11.3% -19.9% -6.8% -3.8% +1.1% +28.2% +55.0% +47.7% +42.3% +32.4%
Total comprehensive income (USD) -7.77M -2.17M -29M -57M -78.9M -152M -157M -184M -167M -134M
Comprehensive income to owners (USD) -7.77M -2.17M -29M -57M -78.9M -152M -157M -184M -167M -134M
Provision for credit losses (USD) 620,000 — — — — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 2.2% — — — — — — — — —
Reported Mar 29, 2019 Mar 29, 2019 Mar 29, 2019 Mar 17, 2020 Mar 5, 2021 Mar 2, 2022 Feb 28, 2023 Feb 27, 2024 Feb 26, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

ATEC Reports Third Quarter Financial Results Bull 4 Bear 3 Results

October 29, 2026

  • Download (opens in new window)

  • Total revenue of $221 million, up 13% year-over-year

  • Surgical revenue of $202 million increased 14%

  • Case volumes grew 20% and net new surgeon users increased 25%

CARLSBAD, Calif.--(BUSINESS WIRE)-- Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended September 30, 2026, and business highlights.

Third Quarter 2026 Financial Results

Quarter Ended September 30, 2026
Total revenue $221 million
GAAP gross margin 71.5%
Non-GAAP gross margin 71.9%
GAAP operating expenses $155 million
Non-GAAP operating expenses $137 million
GAAP net income / (loss) ($5) million
Non-GAAP net income / (loss) $15 million
Non-GAAP adjusted EBITDA $38 million
Non-GAAP adjusted EBITDA margin 17.3%
Ending cash balance $80 million

Third Quarter Highlights

  • Surgical revenue of $202 million increased 14%, up $25 million year-over-year
  • Surgical hardware contributed $26 million to surgical growth and increased 17% year-over-year
  • Adjusted EBITDA of $38 million, or 17% of revenue, expanded 400 basis points year-over-year
  • Generated $6 million free cash flow with continued, positive trailing twelve-month free cash flow
  • Tommy Carls joined the senior leadership team as EVP of Data Intelligence & Strategy

“Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment,” said Pat Miles, Chairman and Chief Executive Officer. “We own and are addressing that shortfall, and going forward, improving biologics performance is a clear priority for us. At the same time, we continued to see very strong demand for our procedural solutions, with hardware revenue growing 17%, case volumes growing approximately 20%, and new surgeon adoption increasing 25%. These results reinforce our confidence in our procedure-focused strategy and the clinical value of our ecosystem. The disciplined execution of biologics is required to realize full procedural revenue translation, while building the foundation for the longer-term opportunity with OsteoAdapt (Theradaptive). We remain bullish on our ability to make continued progress toward increasingly profitable growth.”

Financial Outlook for the Full Year 2026

For fiscal year 2026, the Company now expects total revenue of approximately $862 million, including approximately $789 million of surgical revenue and approximately $73 million of EOS revenue. This outlook represents approximately 13% total revenue growth and approximately 15% surgical revenue growth for the year.

The Company now expects adjusted EBITDA of approximately $137 million, reflecting continued year-over-year profitability expansion. The Company also expects approximately $10 million of free cash flow for fiscal year 2026.

Financial Results Webcast

The Company will host a live webcast today at 1:30 p.m. PT / 4:30 p.m. ET. To access the live webcast, please use this link or visit the Investor Relations Events & Presentations section of ATEC’s corporate website.

A replay of the webcast will remain available through the Investor Relations section of ATEC’s corporate website for twelve months.

Analyst Webcast Q&A Participation

To participate in the question-and-answer session, analysts must register in advance using this link. Upon registration, access details, including a unique code, will be provided via email.

Non-GAAP Financial Information

To supplement the Company’s financial statements presented in accordance with generally accepted accounting principles in the United States of America (GAAP), the Company reports certain non-GAAP financial measures listed below under “Non-GAAP Financial Measures.” The Company believes that these non-GAAP financial measures provide investors with an additional tool for evaluating the Company's core performance, which management uses in its own evaluation of continuing operating performance, and provides a baseline for assessing the Company’s future earnings potential. The Company’s non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company’s industry, as other companies in the industry may calculate non-GAAP financial measures differently, particularly related to non-recurring, unusual items. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. We have not reconciled our non-GAAP financial measures for the full year 2026 because certain items that impact these figures are either uncertain or outside our control and cannot be reasonably predicted. Accordingly, a reconciliation of forward-looking, non-GAAP financial measures is not available. Included below are definitions of the non-GAAP financial measures the Company uses.

Non-GAAP Financial Measures

Free cash flow: Calculated by subtracting capital expenditures from cash flow provided by or used in operating activities. Management uses free cash flow to measure progress on its capital efficiency and cash flow initiatives.

Non-GAAP Gross Profit and Non-GAAP Gross Margin: Non-GAAP gross profit represents GAAP gross profit with adjustments to exclude the impact of certain items recorded to cost of goods sold. Such potential adjustments are described within the section below under "Non-GAAP Adjustments" and included in the non-GAAP reconciliation attached below. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of GAAP net sales.

Non-GAAP Operating Expenses: Non-GAAP operating expenses represent GAAP operating expenses, such as sales, general, and administrative expense, and research and development expense, with adjustments to exclude the impact of certain items recorded in GAAP operating expenses. Such potential adjustments are described within the section below under "Non-GAAP Adjustments" and included in the non-GAAP reconciliation.

Non-GAAP Net Income (Loss) and Non-GAAP EPS: Non-GAAP net income (loss) represents GAAP net loss with adjustments to exclude the impact of certain items recorded in GAAP net loss. Such potential adjustments are described within the sections below under "Non-GAAP Adjustments" and included in the non-GAAP reconciliation. Non-GAAP EPS represents non-GAAP net income (loss) divided by weighted-average shares outstanding.

EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin: EBITDA represents earnings before non-operating income/expense, taxes, depreciation and amortization. Adjusted EBITDA consists of EBITDA with adjustments to exclude certain items described within the section below under "Non-GAAP Adjustments" and included in the non-GAAP reconciliation. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of GAAP net sales.

Non-GAAP Adjustments

The Company's non-GAAP financial measures reflect the exclusion of the following items:

Amortization of acquired intangible assets: Represents amortization expense associated with intangible assets including, but not limited to customer relationships, intellectual property, and trade names acquired in business combinations and asset acquisitions. This adjustment does not include amortization from other intangibles.

Litigation-related expenses: We are involved in various litigation matters that from time to time result in settlements. Litigation matters can vary in their characteristics, frequency and significance to our operating results and core business operations. We review litigation matters from both a qualitative and quantitative perspective to determine whether such matters are a normal and recurring part of our business. We include in our GAAP financial statements litigation fees and settlement expenses that we determine to be normal, recurring and routine to our business. When we determine that certain litigation matters are not normal and recurring to our core business operations, we believe excluding these expenses will provide our management and investors with useful incremental information. Litigation fees and settlement expenses excluded from our non-GAAP financial measures in the periods presented relate primarily to patent litigation and other litigation matters that relate directly to the business transformation that we started in 2018 and are discussed more fully in our periodic reports filed with the Securities and Exchange Commission.

Purchase accounting adjustments on acquisitions: Includes non-cash expenses incurred as a result of fair value step-ups associated with tangible assets acquired in business combinations or asset acquisitions.

Restructuring expenses: From time to time, in order to realign the Company’s operations or to realize synergies from acquisitions, the Company may eliminate roles or restructure its operations and footprint. In such cases, the Company may incur one-time severance and personnel costs associated with workforce reductions, or costs associated with exiting and/or relocating facilities. We exclude these costs as we do not consider such amounts to be part of the ongoing operations.

Stock-based compensation: Stock-based compensation is charged to cost of revenue and operating expenses. We exclude stock-based compensation from certain of our non-GAAP financial measures because we believe that excluding these non-cash expenses provides meaningful supplemental information regarding operational performance. Because of the variety of equity awards used by companies, the varying methodologies for determining stock-based compensation expense, the subjective assumptions involved in those determinations, and the volatility in valuations that can be driven by market conditions outside the Company’s control, the Company believes excluding stock-based compensation expense enhances the ability of management and investors to understand and assess the underlying performance of its business over time.

Transaction-related expenses: Represent one-time costs incurred in connection with business combinations, asset acquisitions, or debt financing and modification activities. These expenses may include, but are not limited to, legal and advisory fees, due diligence costs, contract termination charges, and other third-party expenses directly related to the planning or execution of these transactions. We exclude these costs because they can vary significantly from period to period and are not indicative of the underlying trends in our core business.

Foreign currency exchange impact: Gains and losses related to foreign currency transactions, which are recorded as other income (expense), net. Management excludes these items when evaluating the Company's operating results as they are primarily non-cash and non-operating in nature.

Loss on debt extinguishment: Represents charges recognized in connection with the early repayment, refinancing, or settlement of debt, including write-offs of unamortized debt discounts, premiums, or deferred financing costs, and any associated prepayment penalties. We exclude these items from non-GAAP results because they are non-recurring in nature, not indicative of ongoing operating performance, and can vary significantly from period to period based on financing activity.

Loss (gain) on derivative liability: Represents non-cash fair value adjustments associated with embedded derivative features related to our convertible debt. These mark-to-market changes are driven by fluctuations in our stock price and other valuation inputs, and do not reflect current operating performance. We exclude these amounts from non-GAAP results because they are non-cash, volatile, and unrelated to the Company’s core business operations.

Non-cash interest expense: Consists primarily of interest expense related to the amortization of debt discounts, deferred financing costs, and other non-cash components associated with our convertible notes and other long-term debt instruments. We exclude this item from non-GAAP net income because it is non-cash in nature and does not reflect our core operating performance or current period cash expenditures.

Long-term income tax rate adjustment: The Company employs a structural long-term projected non-GAAP income tax rate of 26% for greater consistency across reporting periods. This long-term projected non-GAAP tax rate reflects historical and expected tax positions and excludes any benefit from deferred tax assets or valuation allowance changes. The long-term rate considers various factors, including the Company’s anticipated tax structure, its tax positions in different jurisdictions, and current impacts from key U.S. legislation where the Company operates. We will reevaluate this tax rate, as necessary, for events such as major changes in the U.S. tax environment, substantial changes in the Company’s geographic earnings mix due to acquisition activity, or other shifts in the Company’s strategy or business operations.

Other non-recurring expenses: These represent items that are unusual or infrequent in nature and that we believe are not indicative of our ongoing operating performance. Examples may include discrete costs associated with tax strategy implementation or one-time expenses related to customer restructuring or reorganization events. We evaluate such items based on their nature and significance and disclose material adjustments in our non-GAAP reconciliations.

About Alphatec Holdings, Inc.

ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S., and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation Machine™ is focused on developing new approaches that integrate seamlessly with the Company’s expanding InformatiX™ platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC’s vision is to be the Standard Bearer in Spine. For more information, visit us at www.atecspine.com .

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company's revenue, balance sheet, growth, adjusted EBITDA, profitability, free cash flow, and financial outlook and commitments; planned product launches, timelines, introductions, regulatory submissions or clearances; and the Company’s ability to compel surgeon adoption, drive procedural growth, improve biologics performance, and gain market share. Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the pipeline; the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company’s products by the surgeon community; the Company’s inability to improve biologics performance and product mix; competitive pressures and market dynamics; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third-party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to achieve profitability; uncertainty of additional funding and the form of such funding; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company's intellectual property; and the Company’s ability to meet its financial obligations. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the U.S. Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

ALPHATEC HOLDINGS, INC.
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
Three Months Ended Nine Months Ended
September 30 September 30
2026 2025 2026 2025
(unaudited) (unaudited)
Revenue from products and services $ 221,172 $ 196,503 $ 626,793 $ 551,227
Cost of sales 62,926 59,203 177,973 168,830
Gross profit 158,246 137,300 448,820 382,397
Operating expenses:
Research and development 18,004 18,679 53,738 53,987
Sales, general and administrative 132,505 124,303 403,563 369,827
Litigation-related expenses 593 6,520 1,032 20,327
Amortization of acquired intangible assets 3,899 3,731 11,731 11,187
Restructuring expenses — — — 378
Total operating expenses 155,001 153,233 470,064 455,706
Operating income (loss) 3,245 (15,933 ) (21,244 ) (73,309 )
Other expense, net:
Cash interest expense, net (4,097 ) (5,312 ) (13,424 ) (15,957 )
Non-cash interest expense, net (6,518 ) (7,566 ) (19,876 ) (17,071 )
Loss on debt extinguishment — — (11,883 ) (17,576 )
Gain on derivative liability — — — 620
Other (expense) income, net (95 ) 307 (519 ) 1,637
Total other expense, net (10,710 ) (12,571 ) (45,702 ) (48,347 )
Net loss before taxes (7,465 ) (28,504 ) (66,946 ) (121,656 )
Income tax (benefit) provision (1,994 ) 74 (1,788 ) (27 )
Net loss $ (5,471 ) $ (28,578 ) $ (65,158 ) $ (121,629 )
Net loss per share, basic and diluted $ (0.03 ) $ (0.19 ) $ (0.42 ) $ (0.81 )
Weighted average shares outstanding, basic and diluted 157,376 151,401 156,021 149,373
Stock-based compensation included in:
Cost of sales $ 643 $ 414 $ 2,172 $ 4,010
Research and development 2,842 3,307 10,448 11,110
Sales, general and administrative 10,468 12,658 43,139 39,201
$ 13,953 $ 16,379 $ 55,759 $ 54,321
Alphatec Holdings, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
September 30, 2026 December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents $ 79,936 $ 160,806
Accounts receivable, net 110,803 97,304
Inventories 206,873 169,444
Prepaid expenses and other current assets 29,553 23,322
Total current assets 427,165 450,876
Property and equipment, net 139,698 135,324
Right-of-use assets 47,723 31,225
Goodwill 73,963 75,208
Intangible assets, net 96,455 93,454
Other assets 11,741 5,121
Total assets $ 796,745 $ 791,208
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY
Current liabilities:
Accounts payable $ 61,626 $ 40,893
Accrued expenses and other current liabilities 98,855 97,019
Contract liabilities 11,643 10,439
Short-term debt 5,303 64,526
Current portion of operating lease liabilities 3,340 6,298
Total current liabilities 180,767 219,175
Total long-term liabilities 594,677 536,004
Redeemable preferred stock 23,603 23,603
Stockholders' (deficit) equity (2,302 ) 12,426
Total liabilities and stockholders' (deficit) equity $ 796,745 $ 791,208
Alphatec Holdings, Inc.
Reconciliation of Non-GAAP Financial Measures
(in thousands)
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
(unaudited)
Gross profit, GAAP $ 158,246 $ 137,300 $ 448,820 $ 382,397
Add: amortization of acquired intangible assets 65 65 196 179
Add: stock-based compensation 643 414 2,172 4,010
Non-GAAP gross profit $ 158,954 $ 137,779 $ 451,188 $ 386,586
Gross margin, GAAP 71.5 % 69.9 % 71.6 % 69.4 %
Add: amortization of acquired intangible assets — % — % — % — %
Add: stock-based compensation 0.3 % 0.2 % 0.3 % 0.7 %
Non-GAAP gross margin 71.9 % 70.1 % 72.0 % 70.1 %
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
(unaudited)
Operating expenses, GAAP $ 155,001 $ 153,233 $ 470,064 $ 455,706
Adjustments:
Stock-based compensation (13,310 ) (15,965 ) (53,587 ) (50,311 )
Litigation-related expenses (593 ) (6,520 ) (1,032 ) (20,327 )
Amortization of acquired intangible assets (3,899 ) (3,731 ) (11,731 ) (11,187 )
Restructuring expenses — — — (378 )
Non-GAAP operating expenses $ 137,199 $ 127,017 $ 403,714 $ 373,503
Alphatec Holdings, Inc.
Reconciliation of Non-GAAP Financial Measures
(in thousands)
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
(unaudited)
Net loss, GAAP $ (5,471 ) $ (28,578 ) $ (65,158 ) $ (121,629 )
Cash interest expense, net 4,097 5,312 13,424 15,957
Non-cash interest expense, net 6,518 7,566 19,876 17,071
Loss on debt extinguishment — — 11,883 17,576
Gain on derivative liability — — — (620 )
Other (expense) income, net 95 (307 ) 519 (1,637 )
Income tax (benefit) provision (1,994 ) 74 (1,788 ) (27 )
Depreciation expense 15,789 14,889 45,578 45,655
Amortization expense 4,677 4,267 13,820 12,736
EBITDA 23,711 3,223 38,154 (14,918 )
Add back significant items:
Stock-based compensation 13,953 16,379 55,759 54,321
Litigation-related expenses 593 6,520 1,032 20,327
Restructuring expenses — — — 378
Adjusted EBITDA $ 38,257 $ 26,122 $ 94,945 $ 60,108
Adjusted EBITDA margin 17.3 % 13.3 % 15.1 % 10.9 %
Adjusted EBITDA margin expansion 400 bps 420 bps
Three Months Ended Nine Months Ended
September 30, September 30,
2026 2025 2026 2025
(unaudited)
Net loss, GAAP $ (5,471 ) $ (28,578 ) $ (65,158 ) $ (121,629 )
Stock-based compensation 13,953 16,379 55,759 54,321
Litigation-related expenses 593 6,520 1,032 20,327
Amortization of acquired intangible assets 3,964 3,796 11,927 11,366
Restructuring expenses — — — 378
Loss on debt extinguishment — — 11,883 17,576
Gain on derivative liability — — — (620 )
Non-cash interest expense, net 6,518 7,566 19,876 17,071
Foreign currency exchange impact 177 (29 ) 621 (648 )
Long-term income tax rate adjustment (4,949 ) (1,563 ) (9,422 ) 517
Non-GAAP net income (loss) $ 14,785 $ 4,091 $ 26,518 $ (1,341 )
Non-GAAP net income (loss) per share $ 0.09 $ 0.03 $ 0.17 $ (0.01 )
Weighted average shares outstanding, basic and diluted 157,376 151,401 156,021 149,373

Investor/Media Contact:
Robert Judd
Investor Relations
(760) 494-6790
[email protected]

Company Contact:
J. Todd Koning
Chief Financial Officer
[email protected]

Source: Alphatec Holdings, Inc.

View All News

October 19, 2026

CARLSBAD, Calif--(BUSINESS WIRE)-- Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2026 financial results on October 29, 2026, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET.

Webcast

To access the live webcast, please use this link or visit the Events & Presentations section of ATEC’s Investor Relations website.

Analyst Participation

To participate in the question-and-answer session, analysts must register in advance using this link . After registering, participants will receive access details, including a unique code, via email.

Replay

A replay of the webcast will be available for 12 months in the Investor Relations section of ATEC’s corporate website.

About Alphatec Holdings, Inc.

ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation MachineTM is focused on developing new approaches that integrate seamlessly with the Company’s expanding InformatiXTM platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC’s vision is to be the Standard Bearer in Spine. For more information, visit us at www.atecspine.com .

Investor/Media Contact:
Robert Judd
Investor Relations
(760) 494-6790
[email protected]

Company Contact:
J. Todd Koning
Chief Financial Officer
[email protected]

Source: Alphatec Holdings, Inc.

View All News

September 23, 2026

Accomplished spine executive to advance ATEC's InformatiX strategy

CARLSBAD, Calif.--(BUSINESS WIRE)-- Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced that Thomas "Tommy" Carls has joined the company as Executive Vice President, Data Intelligence and Strategy. Carls will report directly to Chairman and Chief Executive Officer, Pat Miles, and will serve as a member of ATEC's Senior Leadership Team.

In this newly created role, Carls will lead ATEC's development and marketing efforts across EOSedge, EOS Insight, data acquisition and analytics, and the broader InformatiX strategy. His mandate is to focus priorities, connect global teams and capabilities, and accelerate an integrated strategy that turns information about each patient and procedure into actionable clinical insight.

"I have known and trusted Tommy for nearly 30 years,” said Miles. “He has spent his career translating complex clinical needs into technologies that meaningfully advance spine surgery. Tommy is a student of spine. His depth of experience across implants, enabling technologies, imaging, software and clinical strategy makes him uniquely qualified to lead this next phase of our evolution. I am confident Tommy will help us accelerate the use of data and predictive analytics to make spine surgery better informed, more reproducible and personalized."

ATEC has assembled a procedural ecosystem spanning EOS imaging, EOS Insight, surgical planning, Valence navigation and robotics, SafeOp neuromonitoring, and patient-specific solutions. By connecting those capabilities through InformatiX, ATEC intends to apply data and predictive analytics to inform decisions before, during and after surgery, improve the reproducibility of surgical execution, and create a learning system that advances spine care over time.

Carls brings more than 3 decades of leadership and innovation experience in spine and medical technology. Throughout his career, Carls has helped develop and launch market-leading technologies across spinal implants, enabling technologies, image-guided surgery and robotics. He previously served as Vice President of Product and Clinical at Proprio Vision, where he helped advance an artificial intelligence-enabled surgical navigation platform. Before Proprio, Carls spent more than two decades with Sofamor Danek and Medtronic in numerous executive roles, spanning engineering, product development, marketing and global research and development. He holds more than 80 patents. Carls earned a Bachelor of Science degree in mechanical engineering from Tulane University and a Master of Business Administration from the University of Memphis.

"ATEC has assembled a distinctive set of technologies across imaging, procedural planning, navigation and robotics, neuromonitoring, and patient-specific solutions," Carls said. "The opportunity is to connect those capabilities and apply data and predictive analytics, so a patient-specific plan becomes a shared source of truth across the continuum of care. This will inform better decisions, improve execution and create a learning system that advances outcomes over time. I am excited to join Pat and the high-performing ATEC team, to help bring that vision to life."

About Alphatec Holdings Inc.

ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC's Organic Innovation Machine™ is focused on developing new approaches that integrate seamlessly with the Company's expanding InformatiX™ platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC's vision is to be the Standard Bearer in Spine. For more information, visit www.atecspine.com .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Forward-looking statements include, among other things, statements regarding the Company's strategy; the integration of its technologies, teams and capabilities; the use of data and predictive analytics; and the anticipated clinical or commercial benefits of its InformatiX platform and procedural ecosystem. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

Important factors include the Company's ability to execute its strategic operating plan, develop and integrate new products and technologies, obtain and maintain regulatory clearances or approvals, achieve surgeon acceptance, protect intellectual property, manage product liability and litigation exposure, and address other risks described in the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor and Media Contact
Robert Judd
Investor Relations
(760) 494-6790
[email protected]

Company Contact
J. Todd Koning
Chief Financial Officer
[email protected]

Source: Alphatec Holdings, Inc.

View All News

Prompts

Alphatec Holdings, Inc. (ticker ATEC), listed in United States.

ETFs Holding Alphatec Holdings, Inc.

ETF Weight in ETF Shares Market value As of
TMFS 3.98% 247,414 $ 2.318M Aug 31, 2026
AFSC 1.94% 20,403 $ 194.237K Jul 31, 2026
LFSC 1.11% 149,732 $ 1.403M Aug 31, 2026
TMFG 0.87% 329,824 $ 3.09M Aug 31, 2026
RUSC 0.22% 19,973 $ 172.766K Jun 30, 2026
ORR short -0.21% -109,338 $ -760K Nov 18, 2026
FSEG 0.17% 1,130 $ 9,774.50 Jun 30, 2026
ESSC 0.14% 5,343 $ 50.865K Jul 31, 2026
FESM 0.12% 771,112 $ 6.67M Jun 30, 2026
PSC 0.11% 305,742 $ 2.645M Jun 30, 2026
RESM 0.05% 207 $ 1,790.55 Jun 30, 2026
FEAC 0.05% 1,392 $ 12.041K Jun 30, 2026
DFAS 0.00% 53,979 $ 381.092K Nov 12, 2026
MSSM 0.00% 766 $ 7,177.42 Aug 31, 2026
TMFM 0.00% 116 $ 1,086.92 Aug 31, 2026
DFUS 0.00% 424 $ 2,993.44 Nov 12, 2026
DFAC 0.00% 942 $ 6,650.52 Nov 12, 2026
AVUQ 0.00% 352 $ 2,386.56 Nov 16, 2026